In order to discover additional drugs and pathways that might inhibit growth of NSCLC with an exon 20 mutant EGFR, we screened with a short-hairpin library for synergism with gefitinib [16-20] and identified several molecular biological pathways and pharmaceutical compounds that inhibited these TKI-resistant NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.